-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

1250 Derivation and External Validation of a Venous Thromboembolism Risk Prediction Model in Patients with Acute Lymphoblastic Leukemia Receiving Asparaginase Therapy

Program: Oral and Poster Abstracts
Session: 332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Poster I
Hematology Disease Topics & Pathways:
Research, Bleeding and Clotting, Lymphoid Leukemias, ALL, Adult, Epidemiology, Clinical Practice (Health Services and Quality), Clinical Research, Thromboembolism, Supportive Care, Diseases, Thrombotic disorders, Treatment Considerations, Lymphoid Malignancies, Study Population, Human
Saturday, December 7, 2024, 5:30 PM-7:30 PM

Daniela R Anderson, MD1*, Radhika Gangaraju, MD2, Wafik Sedhom, MD3*, Eva N. Hamulyák, MD, PhD4,5*, Tzu-Fei Wang, MD, MPH6, Kristen M. O'Dwyer, MD7, Brian J. Carney, MD8, Chandrasekar Muthiah, MD9, Michaela Liedtke, MD10, Talha Badar, MD11, Shai O. Shimony, MD12, Renana Robinson, MD13,14*, Kristen M. Sanfilippo, MD15, Andriy Derkach, PhD16*, Shira N. Dinner, MD3, Bart J. Biemond, MD, PhD5*, Kimberly H Seymour, MD, MS17, David Nemirovsky16*, Leah A Goldberg, MD18*, Anjani D Kapadia, MD, BA19*, Hannah Levavi, MD20, Michal Bar-Natan, MD21, Grace Van Hyfte, MSc22*, Karan Bansal, MPH2*, Marc Carrier, MD, MSc23, Jill Fulcher, MD, PhD, FRCPath24, Anke M Gerrits, MD4*, Selina Luger, MD, FRCPC25, Guru Subramanian Guru Murthy, MBBS26, Marlise R. Luskin, MD12, Ofir Wolach, MD14,27*, William Shomali, MD28, Jeffrey I. Zwicker, MD29,30, Wendy Stock, MD31 and Avi Leader, MD29,32

1Department of Family Medicine, University of Chicago, Chicago, IL
2Institute for Cancer Outcomes and Survivorship, University of Alabama at Birmingham, Birmingham, AL
3Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL
4Department of Internal Medicine, OLVG, Amsterdam, Netherlands
5Department of Hematology, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands
6Department of Medicine, Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON, Canada
7Wilmot Cancer Institute, University of Rochester, Rochester, NY
8Division of Hematology and Hematologic Malignancies, Beth Israel Deaconess Medical Center, Boston, MA
9Division of Hematology-Oncology, Medical College of Wisconsin, Milwaukee, WI
10Division of Hematology, Department of Medicine, Stanford Health Care, Stanford, CA
11Department of Hematology/Oncology, Mayo Clinic, Jacksonville, FL
12Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
13Faculty of medical and health sciences, Tel Aviv University, Tel Aviv, Israel
14Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, Israel
15Washington University School of Medicine St Louis, Chesterfield, MO
16Department of Biostatistics and Epidemiology, Memorial Sloan Kettering Cancer Center, New York, NY
17University of Rochester Medical Center, Rochester
18Department of Internal Medicine, University of Chicago Medical Center, Chicago, IL
19Department of Internal Medicine and Pediatrics, University of Chicago Medical Center, Chicago, IL
20Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, Brooklyn, NY
21Weill Cornell Medicine and The New York Presbyterian Hospital in New York City, New York, NY
22Tisch Cancer Institute, Icahn School of Medicine At Mount Sinai, New York, NY
23Department of Medicine, University of Ottawa at The Ottawa Hospital and the Ottawa Hospital Research Institute, Ottawa, ON, Canada
24Department of Medicine, University of Ottawa at The Ottawa Hospital and the Ottawa Hospital Research Institute, Ottawa, ON, CAN
25Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, PA
26Division of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI
27Tel Aviv University, The Faculty of Medicine & Health Sciences, Tel Aviv, Israel
28Department of Medicine, Division of Hematology, Stanford University School of Medicine, Los Altos, CA
29Weill Cornell Medical College, New York, NY
30Memorial Sloan Kettering Cancer Center, New York, NY
31Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL
32Hematology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY

Background: Patients with acute lymphoblastic leukemia (ALL) receiving L-asparaginase (ASP) based induction therapy have a high risk of venous thromboembolism (VTE). Studies investigating universal thromboprophylaxis strategies have yielded sub-optimal results. Risk prediction models are needed to identify high-risk patients who would be candidates for intensification of thromboprophylaxis, and lower risk patients who are unlikely to benefit.

Aims: Derive and externally validate a risk prediction model for VTE in patients with ALL receiving ASP therapy.

Methods: We conducted a multicenter, international, cohort study of patients with newly-diagnosed ALL receiving ASP-based induction therapy (≥18yrs). The derivation and external validation cohorts included 306 and 97 patients without VTE prior to ASP therapy, respectively. Patients on therapeutic anticoagulation at index were excluded. Patients were followed from date of first ASP dose for 100 days post ALL diagnosis or until VTE, therapeutic anticoagulation or death. Candidate predictors were documented at ALL diagnosis and included demographics, disease and treatment characteristics, VTE history, comorbidities, thromboprophylaxis, complete blood count, fibrinogen and d-dimer. D-dimer was only analyzed within the 7 derivation cohort centers who routinely tested this at ALL diagnosis with <20% missing values. Primary outcome was VTE at any site (centrally confirmed). Secondary outcomes included major bleeding by ISTH criteria. Cause-specific Cox proportional hazard regression was performed to identify VTE risk factors in the derivation cohort while treating death as a competing event. Variables with p-value <0.1 on univariable analysis were included in a multivariable model and subsequently used in the risk model if p-value <0.05. Lastly, the derived VTE risk prediction model was tested in the external validation cohort for association with time to VTE using cause-specific Cox proportional hazard model. All analyses were stratified by center and use of low molecular weight heparin prophylaxis (at any dose on the date of first ASP dose).

Results: The cumulative incidence of VTE in the derivation cohort was 17% at 30 days (95% confidence interval [CI] 13% - 21%) and 22% at 90 days (95% CI 17% - 27%). The multivariable model included hyperlipidemia (hazard ratio [HR] 1.35; 95% CI 0.56 - 3.27), body mass index ≥ 25 kg/m² (HR 1.49; 95% CI 0.75 - 2.95), platelet count ≥ 25 x 10⁹/L (HR 1.42; 95% CI 0.67 - 3.00), increasing hemoglobin per 1 g/dL (HR 1.17; 95% CI 1.03 - 1.32) and d-dimer ≥ 1 µg FEU/mL (HR 2.68; 95% CI 1.08 - 6.66). Hemoglobin as a continuous variable and d-dimer ≥ 1 µg FEU/mL were included in the final model and used to create a risk score which was weighted by estimated log-HR sum of these risk factors. The lowest risk quartile (risk score below 2.1) successfully differentiated between a lower 30-day cumulative VTE incidence (4%, 95% CI 0.72% - 12%) compared with the other quartiles (20%, 95% CI 14% - 27%; HR 4.40, 95% CI 1.54 - 12.5) which were defined as high risk (score ≥2.1). The risk score’s negative predictive value (NPV) for VTE at 30 days was 96% and positive predictive value (PPV) was 20%.

The validation cohort (n=97 from 3 external cohorts with routine d-dimer measurement) included 16 (16.5%) patients in the low-risk group and 81 (83.5%) in the high-risk group, with a 30-day VTE incidence of 6.3% (95% CI 0% - 17%) and 21% (95% CI 12% - 30%), respectively (HR 6.22; 95% CI 0.85 - 45.8; p = 0.073)). The NPV (93.7%) and PPV (21%) were comparable to the derivation cohort.

The 30-day incidence of major bleeding was 0% (95% CI NR - NR) in low-risk patients (HR 1.36; 95% CI 0.27 – 6.77) and 2.0% (95% CI 0.55% - 5.4%) in the high-risk group.

Conclusion: Patients with ALL receiving ASP induction therapy have a 17% VTE risk at 30 days. We derived and externally validated a VTE risk prediction model based upon d-dimer and hemoglobin. This model successfully identifies at least 16.5% of patients with ALL who have a low VTE risk after ASP treatment. Using this model, novel prevention strategies which may be associated with cost and risk could now be tailored to patients with higher risk. Prospective studies are needed to validate the model’s performance and role in VTE risk management.

Disclosures: Gangaraju: Takeda: Consultancy; Bayer: Consultancy; Alexion: Consultancy; Sanofi: Consultancy, Honoraria, Research Funding. Wang: Servier: Honoraria; Leo Pharma: Research Funding; Valeo: Honoraria. Carney: Sanofi: Honoraria, Membership on an entity's Board of Directors or advisory committees. Liedtke: Biomea: Research Funding; Kite: Membership on an entity's Board of Directors or advisory committees; Nexcella: Membership on an entity's Board of Directors or advisory committees; Seagen: Research Funding; BMS: Membership on an entity's Board of Directors or advisory committees, Research Funding; Caelum/Alexion: Research Funding; Gilead: Research Funding; Janssen: Membership on an entity's Board of Directors or advisory committees, Research Funding; Abbvie: Membership on an entity's Board of Directors or advisory committees, Research Funding; Allogene: Research Funding. Badar: pfizer: Other: Advisory board; Takeda: Other: advisory board ; Morphosys: Other: Advisory Board. Dinner: Rigel: Consultancy; Pfizer: Consultancy; Kite: Consultancy. Levavi: Sobi: Consultancy, Other: Advisory Board. Bar-Natan: Incyte: Research Funding; BMS: Research Funding; Amgen: Research Funding. Carrier: Sanofi: Consultancy; Regeneron: Consultancy; Anthos: Consultancy; Servier: Consultancy; Bayer: Consultancy; BMS: Consultancy; Pfizer: Consultancy, Other: Grants paid to institution; Leo Pharma: Consultancy, Other: Grants paid to institution. Fulcher: Pfizer: Honoraria; Amgen: Honoraria; AbbVie: Honoraria; Gilead: Honoraria; Jazz Pharmaceuticals: Honoraria; Novartis: Honoraria. Luger: Marker Therapeutics: Membership on an entity's Board of Directors or advisory committees; Takeda: Research Funding; Daiichi Sankyo: Membership on an entity's Board of Directors or advisory committees; Novartis: Consultancy, Membership on an entity's Board of Directors or advisory committees; Amgen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; AbbVie: Membership on an entity's Board of Directors or advisory committees; Astellas: Consultancy. Guru Murthy: BMS: Other: Advisory Board; Stemline: Speakers Bureau; Zentalis: Research Funding; Syndax: Other: Advisory Board; Rigel: Speakers Bureau; Pfizer: Other: Advisory board; Merck: Research Funding; Amgen: Consultancy, Speakers Bureau; LOXO/Lilly: Research Funding; BeiGene: Other: Advisory board, Research Funding; Autolus: Other: Advisory board; Schrodinger: Research Funding; Gilead Sciences/Kite: Other: Advisory board, Research Funding. Luskin: Pfizer: Honoraria; Jazz: Honoraria; AbbVie: Research Funding; Novartis: Honoraria, Research Funding; KITE: Honoraria. Wolach: Abbvie, Janssen,: Consultancy, Honoraria, Research Funding; Teva: Honoraria; Pfizer: Honoraria; Medison: Honoraria; Astellas: Honoraria; Amgen: Honoraria. Shomali: Blueprint Medicines: Research Funding; Incyte Inc: Consultancy, Research Funding. Zwicker: Quercegen: Research Funding; Med Learning Group: Consultancy; Parexel: Consultancy; Calyx: Consultancy; BMS: Consultancy; Regeneron: Consultancy, Research Funding; Incyte Corporation: Research Funding; UpToDate: Patents & Royalties; CSL Behring: Other: Personal fees; Sanofi: Other: Personal fees. Stock: Adaptive: Consultancy, Honoraria; Kura: Research Funding; Kura, Servier, Newave, Adaptive, Jazz, Asofarma: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees. Leader: Leo Pharma: Honoraria.

*signifies non-member of ASH